The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Open accessAbstract
BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. RESULTS: Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab, a PD-1 inhibitor, in combination with ipilimumab, a CTLA-4 inhibitor, has shown favourable efficacy outcomes and manageable safety profiles across multiple tumour types.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [39]
In the citing paper
“First-line nivolumab + ipilimumab treatment also produced longer OS than chemotherapy in patients with advanced NSCLC10.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“First-line nivolumab + ipilimumab resulted in a longer duration of OS than chemotherapy in patients with metastatic NSCLC, irrespective of the PD-L1 expression10,28.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“most notably the combination of pembrolizumab and axitinib (an inhibitor of vascular growth factor inhibitor) in renal cell carcinoma.15”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [15]
In the citing paper
“Until now, the FDA has approved the ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1 positive NSCLC, and malignant pleural mesothelioma (Table 5) [132–138].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
In the citing paper
“Moreover, the data of CheckMate-214, CheckMate-227, and CheckMate-743 indicated the superior efficacy of ipilimumab plus nivolumab over the standard targeted therapy or chemotherapy [135–137].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,003
Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer
Mouratidis, P., & ter Haar, G. (2022) · Cancers · doi:10.3390/cancers14030638 · Cited by 40
Roles and therapeutic implications of m6A modification in cancer immunotherapy
Pan, J., Huang, T., Deng, Z., & Zou, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1132601 · Cited by 39
Creemers, J. H. A., Ankan, A., Roes, K. C. B., Schröder, G., Mehra, N., Figdor, C. G., de Vries, I. J. M., & Textor, J. C. (2023) · Nature Communications · doi:10.1038/s41467-023-37933-8 · Cited by 39
Liu, R., Zhu, G., Sun, Y., Li, M., Hu, Z., Cao, P., Li, X., Song, Z., & Chen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304529 · Cited by 40
Plomp, L., Chassepot, H., Psimaras, D., Maisonobe, T., Mensi, E., Léonard-Louis, S., Plu, I., Rozes, A., Tubach, F., Touat, M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101192 · Cited by 40
Landre, T., Guetz, G. D., Chouahnia, K., Fossey-Diaz, V., & Culine, S. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00788-5 · Cited by 42
Gomes, F., Wong, M. L., Battisti, N. M. L., Kordbacheh, T., Kiderlen, M., Greystoke, A., & Luciani, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0986-4 · Cited by 41
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 41
Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
Rytlewski, J. D., Milhem, M. M., & Monga, V. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6041 · Cited by 39
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 41
Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
Jimbu, L., Mesaros, O., Popescu, C., Neaga, A., Berceanu, I., Dima, D. M., Găman, M., & Zdrenghea, M. (2021) · Pharmaceuticals · doi:10.3390/ph14040288 · Cited by 41
Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity
Burton, E. M., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0257 · Cited by 40
Jensen, C., Nissen, N. I., von Arenstorff, C. S., Karsdal, M. A., & Willumsen, N. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02133-z · Cited by 41
Insa, A., Martín-Martorell, P., Liello, R. D., Fasano, M., Martini, G., Napolitano, S., Vicidomini, G., Cappabianca, S., Franco, R., Morgillo, F., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103538 · Cited by 42
Biomarkers for predicting the efficacy of immune checkpoint inhibitors
Wang, C., Wang, H.-N., & Wang, L. (2022) · Journal of Cancer · doi:10.7150/jca.65012 · Cited by 39
Federico, A. D., Giglio, A. D., Gelsomino, F., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac205 · Cited by 40
Wang, Y., Chen, D., Liu, Y., Shi, D., Duan, C., Li, J., Shi, X., Zhang, Y., Yu, Z., Sun, N., et al. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05992-w · Cited by 39
Zhao, J. J., Syn, N. L. X., Tan, B. K. J., Yap, D. W. T., Teo, C. B., Chan, Y. H., & Sundar, R. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01567-z · Cited by 41
Wang, Y., Zou, J., Li, Y., Jiao, X., Wang, Y., Zhuo, N., Gao, M., Gong, J., Li, J., Zhang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.987568 · Cited by 39
Ibáñez‐Molero, S., Vliet, A. V., Poźniak, J., Hummelink, K., Terry, A. M., Monkhorst, K., Sanders, J., Hofland, I., Landeloos, E., Herck, Y. V., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2139074 · Cited by 42
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Yiong, C. S., Lin, T. P., Lim, V., Toh, T. B., & Yang, V. S. (2023) · Biomarker Research · doi:10.1186/s40364-023-00513-5 · Cited by 42
Immune-related encephalitis after immune checkpoint inhibitor therapy
Buckley, M. W., Balaji, A., Brahmer, J. R., Cappelli, L. C., Sharfman, W. H., Fuchs, E. J., Kang, H., Forde, P. M., Gladstone, D. E., Ambinder, R. F., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae186 · Cited by 38
Self-citationInternational consensus on radiotherapy in metastatic non-small cell lung cancer
Zhu, Z., Ni, J., Cai, X., Su, S., Zhuang, H., Yang, Z., Chen, M., Ma, S., Xie, C., Xu, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-644 · Cited by 39
Akbari, H., Taghizadeh‐Hesary, F., & Bahadori, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.12.001 · Cited by 38
Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 40
Chen, B., Chen, Y., Dragomir, M. P., Chi, D., Chen, W., Horst, D. A., Călin, G. A., & Li, Q. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111703 · Cited by 38
He, K., Berz, D., Gadgeel, S. M., Iams, W. T., Bruno, D. S., Blakely, C. M., Spira, A. I., Patel, M. R., Waterhouse, D. M., Richards, D., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.02.016 · Cited by 40
Thummalapalli, R., Ricciuti, B., Bandlamudi, C., Muldoon, D. M., Rizvi, H. A., Elkrief, A., Luo, J., Alessi, J. V., Pecci, F., Lamberti, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1207 · Cited by 38
Self-citationSholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0536-cp · Cited by 38
Friedlaender, A., Kim, C., & Addeo, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00862 · Cited by 38
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Xiong, A., Wang, J., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757993 · Cited by 38
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
Friedlaender, A., Naidoo, J., Banna, G. L., Metro, G., Forde, P. M., & Addeo, A. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102350 · Cited by 38
Xia, H., Zhang, W., Zhang, Y., Shang, X., Liu, Y., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978069 · Cited by 37
Sternschuss, M., Yerushalmi, R., Saleh, R., Amir, E., & Goldvaser, H. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03591-w · Cited by 37
Cucchiara, F., Petrini, I., Romei, C., Crucitta, S., Lucchesi, M., Valleggi, S., Scavone, C., Capuano, A., LIPERI, A. D., Chella, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105643 · Cited by 39
Cutting-Edge Therapies for Lung Cancer
La’ah, A. S., & Chiou, S. (2024) · Cells · doi:10.3390/cells13050436 · Cited by 36
Jiang, Y., Zheng, Y., Zhang, Y., Kong, S., Dong, J., Wang, F., Ziman, B., Gery, S., Hao, J., Zhou, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46785-9 · Cited by 37
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Rina, A., Maffeo, D., Minnai, F., Esposito, M., Palmieri, M., Serio, V. B., Rosati, D., Mari, F., Frullanti, E., & Colombo, F. (2024) · Cancers · doi:10.3390/cancers16162882 · Cited by 44
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers
Floudas, C. S., Goswami, M., Donahue, R. N., Pastor, D. M., Redman, J. M., Brownell, I., Turkbey, E. B., Cordes, L. M., Steinberg, S. M., Manu, M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.6998 · Cited by 38
An annual review of the remarkable advances in lung cancer clinical research in 2019
Cheng, B., Xiong, S., Li, C., Liang, H., Zhao, Y., Li, J., Shi, J., Ou, L., Chen, Z., Liang, P., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.11 · Cited by 36
Solomon, B., Zhou, C. C., Drilon, A. E. D. C., Park, K., Wolf, J., Elamin, Y. Y., Davis, H. M., Soldatenkova, V., Sashegyi, A. I., Bence, A. K., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0935 · Cited by 37
Self-citationBrito, A. B. C., Camandaroba, M. P. G., & de Lima, V. C. C. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13867 · Cited by 39
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Abolghasemi, H., Ghaffari, S. H., Momeny, M., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174404 · Cited by 36
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M. J., Dubinett, S. M., Ferris, A. A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003956 · Cited by 46
Self-citationWang, Q., He, Y., Li, W., Xu, X., Hu, Q., Bian, Z., Xu, A., Tu, H., Wu, M. T., & Wu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887916 · Cited by 36
CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
Lau, A. P. Y., Binstock, S. S. K., & Thu, K. L. (2023) · Cancers · doi:10.3390/cancers15215229 · Cited by 39
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Schenk, E. L., Patil, T., Pacheco, J. M., & Bunn, P. A. (2020) · The Oncologist · doi:10.1002/onco.13590 · Cited by 37
Lung Cancer Stem Cells—Origin, Diagnostic Techniques and Perspective for Therapies
Raniszewska, A., Kwiecień, I., Rutkowska, E., Rzepecki, P., & Domagala-Kulawik, J. J. (2021) · Cancers · doi:10.3390/cancers13122996 · Cited by 38
Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
Potter, D. S., Du, R., Bhola, P. D., Bueno, R., & Letai, A. G. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04029-4 · Cited by 36
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, P., Han, L., Ba, X., Qin, K., & Tu, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.678409 · Cited by 36
Lindsay, C. R., Shaw, E. C., Moore, D. A., Rassl, D. M., Jamal‐Hanjani, M., Steele, N. L., Naheed, S., Dick, C., Taylor, F., Adderley, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01407-9 · Cited by 38
Mondelo‐Macía, P., García, J., León‐Mateos, L., Anido, U., Aguín, S., Abdulkader, I., Sánchez‐Ares, M., Abalo, A., Rodríguez‐Casanova, A., Díaz‐Lagares, Á., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13094 · Cited by 36
Calabrò, L., Rossi, G., Covre, A., Morra, A., & Maio, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01125-8 · Cited by 33
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 37
Reuniting philosophy and science to advance cancer research
Pradeu, T., Daignan‐Fornier, B., Ewald, A. J., Germain, P., Okasha, S., Plutynski, A., Benzekry, S., Bertolaso, M., Bissell, M. J., Brown, J. S., et al. (2023) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12971 · Cited by 37
Zhou, X., Wu, J., Duan, C., & Liu, Y. (2020) · Journal of Immunology Research · doi:10.1155/2020/7890985 · Cited by 35
Immunotherapy-induced Hepatotoxicity: A Review
Cunha, T. D., Wu, G. Y., & Vaziri, H. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00105 · Cited by 37
Borghaei, H., Ciuleanu, T., Lee, J.-S., Płużański, A., Caro, R. B., Gutierrez, M. E., Ohe, Y., Nishio, M., Goldman, J. W., Ready, N., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.11.006 · Cited by 35
Self-citationZhou, C., Qin, Y., Zhao, W. M., Liang, Z., Li, M., Liu, D., Bai, L., Chen, Y., Chen, Y., Cheng, Y. S., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-339 · Cited by 39
Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma
Serritella, A. V., & Shenoy, N. K. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3295 · Cited by 37
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16020340 · Cited by 44
Gravina, A. G., Pellegrino, R., Esposito, A., Cipullo, M., Romeo, M., Palladino, G., Iodice, P., Federico, A., & Troiani, T. (2024) · Cancers · doi:10.3390/cancers16030611 · Cited by 36
Wu, Z., Man, S., Sun, R., Li, Z., Wu, Y., & Zuo, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106613 · Cited by 35
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35
Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions
Montironi, C., Muñoz‐Pinedo, C., & Eldering, E. (2021) · Cancers · doi:10.3390/cancers13020284 · Cited by 38
Zhou, S., Xie, J., Huang, Z., Deng, L., Wu, L., Yu, J., & Meng, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.043 · Cited by 35
Wang, X., Niu, X., An, N., Sun, Y., & Chen, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.611012 · Cited by 36
Ramos‐Paradas, J., Hernández-Prieto, S., Lora, D., Sanchez, E., Rosado, A., Caniego-Casas, T., Carrizo, N., Enguita, A. B., Muñoz-Jimenez, M. T., Rodriguez, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001904 · Cited by 35
Self-citationPerioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Soh, J., Hamada, A., Fujino, T., & Mitsudomi, T. (2021) · Cancers · doi:10.3390/cancers13164035 · Cited by 35
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events
Smithy, J. W., Faleck, D. M., & Postow, M. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1240 · Cited by 35
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 38
T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
Kamakura, D., Asano, R., & Yasunaga, M. (2021) · Pharmaceuticals · doi:10.3390/ph14111172 · Cited by 37
Clinical predictive value of naïve and memory T cells in advanced NSCLC
Zhang, G., Liu, A., Yang, Y., Xia, Y., Li, W., Liu, Y., Zhang, J., Cui, Q., Wang, D., Liu, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996348 · Cited by 35
Choudhury, N. J., Lavery, J. A., Brown, S., de Bruijn, I., Jee, J., Tran, T. N., Rizvi, H. A., Arbour, K. C., Whiting, K. A., Shen, R., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0580 · Cited by 36
Self-citationM7G-related tumor immunity: novel insights of RNA modification and potential therapeutic targets
Han, M., Huang, Q., Li, X., Chen, X., Zhu, H., Pan, Y., & Zhang, B. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.90382 · Cited by 36
PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review)
Wang, S., Liu, C., Yang, C., Jin, Y., Cui, Q., Wang, D., Ge, T., He, G., Li, W., Zhang, G., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14700 · Cited by 35
Ouyang, P., Zhang, J., He, X., Yang, C., Zeng, D., & Xu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1661545 · Cited by 44
Passariello, M., Camorani, S., Vetrei, C., Ricci, S., Cerchia, L., & Lorenzo, C. D. (2020) · Cancers · doi:10.3390/cancers12020331 · Cited by 33
Lamberti, G., Andrini, E., Sisi, M., Federico, A. D., & Ricciuti, B. (2020) · Future Oncology · doi:10.2217/fon-2020-0215 · Cited by 36
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
Liu, W., Zhang, L., Xiu, Z., Guo, J., Wang, L., Zhou, Y., Jiao, Y., Sun, M., & Cai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s255491 · Cited by 34
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 35
Giustini, N., & Bazhenova, L. A. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s235102 · Cited by 36
Zouein, J., Kesrouani, C., & Kourié, H. R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0336 · Cited by 37
E-cadherin on epithelial–mesenchymal transition in thyroid cancer
Zhu, X., Wang, X., Gong, Y., & Deng, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02344-6 · Cited by 36
John, T., Sakai, H., Ikeda, S., Cheng, Y., Kasahara, K., Sato, Y., Nakahara, Y., Takeda, M., Kaneda, H., Zhang, H., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02120-0 · Cited by 33
Self-citationLiu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 36
Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
Chen, H., Yang, W., Xue, X., Li, Y., Jin, Z., & Ji, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986359 · Cited by 34
A novel chemokine‐based signature for prediction of prognosis and therapeutic response in glioma
Fan, W., Wang, D., Li, G., Xu, J., Ren, C., Sun, Z., Wang, Z., Ma, W., Zhao, Z., Bao, Z., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13944 · Cited by 32
Liao, C.-Y., Chen, Y., Wu, Y., Chao, H., Chiu, H., Wang, T., Chen, J.-R., Shiao, T., & Lu, C. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00779-4 · Cited by 35
A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy
Justiz-Vaillant, A. A., Pandit, B. R., Unakal, C. G., Vuma, S., & Akpaka, P. E. (2025) · Antibodies · doi:10.3390/antib14020035 · Cited by 37
Gión, M., Blancas, I., Cortez-Castedo, P., Cortés, A., Marmé, F., Blanch, S., Morales, S. M., Díaz, N., Calvo-Plaza, I., Recalde, S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03734-3 · Cited by 35
Bevins, N., Sun, S., Gaieb, Z., Thorson, J., & Murray, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000613 · Cited by 36
Chen, L., Shi, X., Zhao, J., He, Q., Fan, Y., Xu, W., Shao, Y. W., Yu, X., & Jin, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00480 · Cited by 33
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
Kim, S. Y., & Halmos, B. (2020) · Lung Cancer Management · doi:10.2217/lmt-2020-0003 · Cited by 33
Self-citationRecent developments in cancer research: Expectations for a new remedy
Ando, K., Hu, Q., Kasagi, Y., Oki, E., & Mori, M. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12440 · Cited by 33
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Attili, I., Tarantino, P., Passaro, A., Stati, V., Curigliano, G., & de Marinis, F. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.035 · Cited by 33
Federico, A. D., Giglio, A. D., Parisi, C., Gelsomino, F., & Ardizzoni, A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103302 · Cited by 34
Augustus, E., Zwaenepoel, K., Siozopoulou, V., Raskin, J., Jordaens, S., Baggerman, G., Sorber, L., Roeyen, G., Peeters, M., & Pauwels, P. (2021) · Cancers · doi:10.3390/cancers13071675 · Cited by 33
Hosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Matsumoto, H., Hirano, K., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08048-4 · Cited by 33
Metadata
- Authors
- Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O’Byrne, K. J., Geese, W. J., Bhagavatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Universidad Complutense de Madrid (ES)
- From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology–Germans Trias i Pujol Hospital, Badalona (E.C.C.) — all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K....
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 2020-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2976744492
- Cited by
- 2,823
- References
- 26
- Citations by year
- 2026: 183 · 2025: 316 · 2024: 399 · 2023: 448 · 2022: 516 · 2021: 570 · 2020: 368 · 2019: 18
- FWCI
- 154.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- ipilimumab, non-small cell lung cancer, PD-L1 expression, immune checkpoint inhibitors, combination immunotherapy, overall survival, chemotherapy, PD-1, CTLA-4, long-term benefits, PD-L1-negative tumors, stage IV lung cancer, recurrent lung cancer, immune-related adverse events, immune-related pneumonitis
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
